Tower Research Capital LLC TRC Grows Position in Bausch Health Companies Inc. (NYSE:BHC)

Tower Research Capital LLC TRC boosted its position in shares of Bausch Health Companies Inc. (NYSE:BHC) by 283.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 6,918 shares of the company’s stock after purchasing an additional 5,112 shares during the period. Tower Research Capital LLC TRC’s holdings in Bausch Health Companies were worth $55,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Principal Securities Inc. purchased a new position in Bausch Health Companies in the 4th quarter worth about $31,000. Bfsg LLC bought a new stake in shares of Bausch Health Companies during the fourth quarter valued at approximately $63,000. Ausdal Financial Partners Inc. bought a new stake in shares of Bausch Health Companies during the third quarter valued at approximately $86,000. Jump Financial LLC purchased a new stake in shares of Bausch Health Companies in the third quarter valued at approximately $92,000. Finally, Mitsubishi UFJ Trust & Banking Corp bought a new position in Bausch Health Companies in the third quarter worth approximately $103,000. 78.65% of the stock is owned by hedge funds and other institutional investors.

Bausch Health Companies Stock Performance

BHC traded up $0.18 on Monday, hitting $8.89. The company had a trading volume of 2,665,216 shares, compared to its average volume of 2,782,024. The stock has a market capitalization of $3.25 billion, a price-to-earnings ratio of -5.43 and a beta of 0.85. The stock has a fifty day moving average price of $9.30 and a 200-day moving average price of $8.18. Bausch Health Companies Inc. has a 12-month low of $5.57 and a 12-month high of $11.46.

Bausch Health Companies (NYSE:BHC) last issued its quarterly earnings data on Thursday, February 22nd. The company reported $1.15 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.01 by $0.14. The firm had revenue of $2.41 billion for the quarter, compared to the consensus estimate of $2.29 billion. Bausch Health Companies had a negative net margin of 6.76% and a positive return on equity of 5,147.48%. The company’s quarterly revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.02 EPS. Analysts forecast that Bausch Health Companies Inc. will post 3.95 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Royal Bank of Canada lowered their target price on Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating for the company in a report on Tuesday, April 23rd. StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a report on Wednesday, February 7th. Jefferies Financial Group reduced their price target on shares of Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating for the company in a report on Tuesday, February 20th. Finally, Piper Sandler increased their price objective on shares of Bausch Health Companies from $7.00 to $9.00 and gave the company a “neutral” rating in a research note on Monday. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $11.33.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.